Effects of dexrazoxane for paclitaxel-induced cardiotoxicity

Medical Reserch and Education ›› 2013, Vol. 30 ›› Issue (2): 16-20.

Effects of dexrazoxane for paclitaxel-induced cardiotoxicity

Received:2016-10-09 Revised:2016-10-09 Online:2013-04-25 Published:2013-04-25

Abstract

Abstract: Objective To study the effects of dexrazoxane in preventing paclitaxel-induced cardiotoxicity in rat models and its mechanism. Methods 64 Wistar rats were randomly divided into four groups: Control group, paclitaxel group, paclitaxel + small dose of dexrazoxane group, paclitaxel + large dose of dexrazoxane group. The cardiotoxicity was assessed by measuring serum cardiac troponinl (cTnI), brain natriuretic peptide (BNP), superoxide dismutase (SOD) and malondialdehyde (MDA) at the end of the 8th and 16th weeks. Results At the end of the 8th weeks the differences for cTnI, BNP, SOD, MDA, pathological performance between groups was not statistically significant (P>0.05). At the end of the 16th weeks paclitaxel increased serum cTnI and BNP (P<0.05). The dexrazoxane acceleration the increasing cTnI and BNP (P<0.05). Dexrazoxane + paclitaxel reduce SOD, increased MDA, the difference was statistically significant (P<0.05). The comparison between the different doses of dexrazoxane group was not statistically significant (P>0.05). conclusion The dexrazoxane increase paclitaxel-induced cardiotoxicity through reducing free radical scavenging enzyme activity, resulting in excessive lipid peroxidation products.

Key words: malignant tumour, paclitaxel, dexrazoxane, cardiotoxicity

CLC Number:

References

[1] 车菲菲, 刘瑜, 徐才刚, CHE Fei-fei, LIU Yu, XU Cai-gang. 右丙亚胺对阿霉素引起的心脏毒性防治效果及其机制研究 [J]. 四川大学学报(医学版) 2010.doi:10.3969/j.issn.1672-173X.2010.01.006
[2] 杨兴艳, 薛月珍. 紫杉醇心脏毒性研究进展 [J]. 医药导报 2009.doi:10.3870/yydb.2009.08.033
[3] SIMUNEK T, KLIMTOVA I, KAPLANOVA J. Rabbit model for in vivo study of anthracycline induced heart failure and for the evaluation of protective agents [J]. European Journal of heart failure 2004, 16(04).
[4] Plande J, Platel D, Tariosse L, Robert J. [J]. Toxicology Letters: An International Journal Providing a Forum for Original and Pertinent Contributions in Toxicology Research 2006.
[5] Lebrecht, D, Geist, A, Ketelsen, UP, Haberstroh, J, Setzer, B, Walker, UA. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. [J]. British Journal of Pharmacology 2007, 6(6).
[6] ROBERT J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors [J]. CARDIOVASCULAR TOXICOLOGY 2007, 7(02).
[7] Sepe DM, Ginsberg JP, Balis FM. [J]. The oncologist 2010.
[8] Lopez M, Vici P, Di-Lauro K, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, Maini CL. [J]. Journal of Clinical Oncology 1998.
[9] Heon S, Bernier M, Servant N, Dostanic S, Wang C, Kirby GM, Alpert L, Chalifour LE. [J]. American Journal of Physiology 2003.
[10] TRIMBLE E L, ADAMS J D, VENA D. Paclitaxel for platinum refractory ovarian cancer results from the first 1000 patientsregistered to National Cancer Institute Treatment Referral Center 9103 [J]. Journal of Clinical Oncology 1993, 11(12).
[11] Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. [J]. Circulation 2004, 25(25).
[12] SEIFERT C F, NESSER M E, THOMPSON D F. Dexrazoxane in the prevention of doxorubicin- induced cardiotoxicity [J]. Annals of Pharmacotherapy 1994, 8(09).